^
Association details:
| Biomarker: | NF1 mutation |
|---|---|
| Cancer: | Sarcoma |
| Drug: | vociprotafib (RMC-4630) (PTPN11 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB001 - Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers
Published date:
04/09/2021
Excerpt:
...initial data from a phase 1 trial of RMC-4630 showed anti-tumor activity in tumors harboring diverse mutations in the RAS pathway including KRASG12C, KRASG12D, NF1LOF, and BRAF Class 3....Of the 80 efficacy evaluable patients, there was 1 CR (NF1LOF uterine carcinosarcoma), 1 PR (KRASG12C NSCLC), and 1 unconfirmed PR (KRASG12D NSCLC). Tumor regressions were observed in another 11 patients (-2.4% to -27.1%).
